These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 26613768)

  • 41. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis.
    Seriolo B; Paolino S; Sulli A; Fasciolo D; Cutolo M
    Ann N Y Acad Sci; 2006 Jun; 1069():414-9. PubMed ID: 16855168
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
    Spanakis E; Sidiropoulos P; Papadakis J; Ganotakis E; Katsikas G; Karvounaris S; Bizaki A; Kritikos H; Boumpas DT
    J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
    Navarro JF; Mora C; Muros M; García-Idoate G
    Nephron Clin Pract; 2003; 95(4):c128-35. PubMed ID: 14694274
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study.
    Haraoui B; Cividino A; Stewart J; Guérette B; Keystone EC
    BMC Musculoskelet Disord; 2011 Nov; 12():261. PubMed ID: 22093579
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis.
    Dessein PH; Stanwix AE; Joffe BI
    Arthritis Res; 2002; 4(5):R5. PubMed ID: 12223108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study.
    Taylor PC; Schiff MH; Wang Q; Jiang Y; Zhuang Y; Kurrasch R; Daga S; Rao R; Tak PP; Hsu B
    Ann Rheum Dis; 2018 May; 77(5):658-666. PubMed ID: 29483080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis.
    Peters MJ; Vis M; van Halm VP; Wolbink GJ; Voskuyl AE; Lems WF; Dijkmans BA; Twisk JW; de Koning MH; van de Stadt RJ; Nurmohamed MT
    Ann Rheum Dis; 2007 Jul; 66(7):958-61. PubMed ID: 17314120
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab.
    Provan SA; Berg IJ; Hammer HB; Mathiessen A; Kvien TK; Semb AG
    PLoS One; 2015; 10(6):e0130709. PubMed ID: 26114946
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.
    Curtis JR; John A; Baser O
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1282-91. PubMed ID: 22504829
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis.
    Kawashiri SY; Kawakami A; Yamasaki S; Imazato T; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Nakamura H; Ida H; Origuchi T; Ueki Y; Eguchi K
    Rheumatol Int; 2011 Apr; 31(4):451-6. PubMed ID: 20024554
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis.
    Virone A; Bastard JP; Fellahi S; Capeau J; Rouanet S; Sibilia J; Ravaud P; Berenbaum F; Gottenberg JE; Sellam J
    RMD Open; 2019; 5(2):e000897. PubMed ID: 31413865
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial.
    Giles JT; Sattar N; Gabriel S; Ridker PM; Gay S; Warne C; Musselman D; Brockwell L; Shittu E; Klearman M; Fleming TR
    Arthritis Rheumatol; 2020 Jan; 72(1):31-40. PubMed ID: 31469238
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Tocilizumab on LDL and HDL Characteristics in Patients with Rheumatoid Arthritis. An Observational Study.
    Pierini FS; Botta E; Soriano ER; Martin M; Boero L; Meroño T; Saez MS; Lozano Chiappe E; Cerda O; Citera G; Gandino I; Rosa J; Sorroche P; Kontush A; Brites F
    Rheumatol Ther; 2021 Jun; 8(2):803-815. PubMed ID: 33811316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Im
    Emery P; Burmester GR; Naredo E; Zhou Y; Hojnik M; Conaghan PG
    BMJ Open; 2018 Feb; 8(2):e019007. PubMed ID: 29490959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN; Mavridis AK; Filippatos TD; Vasakos S; Nikas SN; Drosos AA
    J Rheumatol; 2006 May; 33(5):921-3. PubMed ID: 16541480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study.
    Bacchiega BC; Bacchiega AB; Usnayo MJ; Bedirian R; Singh G; Pinheiro GD
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28288972
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis.
    Levi M; Grange S; Frey N
    J Clin Pharmacol; 2013 Feb; 53(2):151-9. PubMed ID: 23436260
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Lipid profile and cardiovascular risk in patients with rheumatoid arthritis: Effect of the disease and of drug therapy].
    Hansel B; Bruckert E
    Ann Endocrinol (Paris); 2010 Sep; 71(4):257-63. PubMed ID: 20416859
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis.
    Daïen CI; Duny Y; Barnetche T; Daurès JP; Combe B; Morel J
    Ann Rheum Dis; 2012 Jun; 71(6):862-8. PubMed ID: 22267329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.